Targets › IL1B
9 programs from 9 companies in 17 trials: 12 Phase 2, 2 Phase 3, 2 Phase 1, 1 Phase 4; Oncology, Immunology, Hematology; next expected readout Dec 2026.
Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. (UniProt, P01584)
Open in Phaseline: the race on IL1B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chinese SLE Treatment And Research Group | Firsekibart Anti-IL-1β monoclonal antibody | IL1B | Phase 4 | Lupus Erythematosus, Systemic | Dec 2027 |
| AbbVie | Lutikizumab Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor | IL1A, IL1B | Phase 3 | Hidradenitis Suppurativa; Rheumatoid Arthritis; Atopic Dermatitis; Ulcerative Colitis … | Dec 2026 |
| University Hospital, Basel, Switzerland | Canakinumab Interleukin-1 beta inhibitor | IL1B | Phase 3 | Postprandial Hypoglycemia | – |
| M.D. Anderson Cancer Center | Canakinumab Interleukin-1 beta inhibitor | IL1B | Phase 2 | Chronic Myelomonocytic Leukemia; Lung Carcinoma | Dec 2026 |
| John Mascarenhas | Canakinumab Interleukin-1 beta inhibitor | IL1B | Phase 2 | Primary Myelofibrosis | Jul 2027 |
| Uma Borate | Canakinumab Interleukin-1 beta inhibitor | IL1B | Phase 2 | Clonal Cytopenia of Undetermined Significance | Dec 2028 |
| Massachusetts General Hospital | Canakinumab Interleukin-1 beta inhibitor | IL1B | Phase 2 | Vascular Inflammation | Jan 2029 |
| NYU Langone Health | Canakinumab Interleukin-1 beta inhibitor | IL1B | Phase 1 | Pancreatic Cancer | – |
| H. Lee Moffitt Cancer Center and Research Institute | Canakinumab Interleukin-1 beta inhibitor | IL1B | Phase 1 | Myelodysplastic Syndromes | – |
Hidradenitis Suppurativa (3) Vascular Inflammation (1) Rheumatoid Arthritis (1) Atopic Dermatitis (1) Ulcerative Colitis (1) Psoriatic Arthritis (1) Crohn's Disease (1) Pancreatic Cancer (1) Primary Myelofibrosis (1) Lupus Erythematosus, Systemic (1) Chronic Myelomonocytic Leukemia (1) Lung Carcinoma (1)
antibody (7), mixed (2)
Massachusetts General Hospital (1) AbbVie (1) NYU Langone Health (1) John Mascarenhas (1) Chinese SLE Treatment And Research Group (1) M.D. Anderson Cancer Center (1) H. Lee Moffitt Cancer Center and Research Institute (1) University Hospital, Basel, Switzerland (1) Uma Borate (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.